Merck & Co. (MRK) PT Raised to $70.00 at Bank of America

Merck & Co. (NYSE:MRK) had its price objective upped by Bank of America from $68.00 to $70.00 in a note issued to investors on Tuesday. The firm currently has a “buy” rating on the stock. Bank of America’s price target suggests a potential upside of 18.10% from the stock’s current price.

A number of other analysts also recently weighed in on MRK. Barclays upgraded Merck & Co. from an “equal weight” rating to an “overweight” rating and increased their price target for the stock from $62.00 to $64.00 in a report on Thursday, April 5th. SunTrust Banks upgraded Merck & Co. from a “hold” rating to a “buy” rating and increased their price target for the stock from $54.00 to $72.00 in a report on Tuesday, January 16th. ValuEngine upgraded Merck & Co. from a “hold” rating to a “buy” rating in a report on Wednesday, January 10th. BMO Capital Markets increased their price target on Merck & Co. from $68.00 to $72.00 and gave the stock an “outperform” rating in a report on Wednesday, January 17th. Finally, DZ Bank upgraded Merck & Co. from a “hold” rating to a “buy” rating in a report on Tuesday, February 13th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and fifteen have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $66.83.

How to Become a New Pot Stock Millionaire

NYSE:MRK traded up $0.62 during trading hours on Tuesday, hitting $59.27. 15,333,132 shares of the company were exchanged, compared to its average volume of 13,000,089. The firm has a market cap of $158,131.55, a P/E ratio of 14.89, a P/E/G ratio of 2.45 and a beta of 0.78. The company has a quick ratio of 1.06, a current ratio of 1.33 and a debt-to-equity ratio of 0.62. Merck & Co. has a one year low of $52.83 and a one year high of $66.41.

Merck & Co. (NYSE:MRK) last announced its earnings results on Friday, February 2nd. The company reported $0.98 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.94 by $0.04. The business had revenue of $10.43 billion during the quarter, compared to analyst estimates of $10.48 billion. Merck & Co. had a return on equity of 28.61% and a net margin of 6.40%. Merck & Co.’s revenue for the quarter was up 3.1% compared to the same quarter last year. During the same period last year, the company earned $0.89 EPS. equities research analysts expect that Merck & Co. will post 4.16 EPS for the current year.

In other news, insider Weir Mirian M. Graddick sold 24,000 shares of the firm’s stock in a transaction dated Monday, April 16th. The stock was sold at an average price of $58.00, for a total value of $1,392,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Wendell P. Weeks sold 5,000 shares of the firm’s stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $53.57, for a total value of $267,850.00. Following the completion of the sale, the director now owns 5,100 shares of the company’s stock, valued at $273,207. The disclosure for this sale can be found here. Company insiders own 0.32% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of the company. Martingale Asset Management L P lifted its position in Merck & Co. by 6.3% in the 2nd quarter. Martingale Asset Management L P now owns 735,229 shares of the company’s stock valued at $47,122,000 after acquiring an additional 43,718 shares in the last quarter. Vantage Investment Advisors LLC lifted its position in Merck & Co. by 31.1% in the 2nd quarter. Vantage Investment Advisors LLC now owns 87,203 shares of the company’s stock valued at $5,589,000 after acquiring an additional 20,706 shares in the last quarter. Jackson Wealth Management LLC lifted its position in Merck & Co. by 9.8% in the 2nd quarter. Jackson Wealth Management LLC now owns 57,127 shares of the company’s stock valued at $3,652,000 after acquiring an additional 5,107 shares in the last quarter. CORDA Investment Management LLC. lifted its position in Merck & Co. by 0.3% in the 2nd quarter. CORDA Investment Management LLC. now owns 229,512 shares of the company’s stock valued at $14,709,000 after acquiring an additional 620 shares in the last quarter. Finally, Financial Counselors Inc. lifted its position in Merck & Co. by 1.2% in the 2nd quarter. Financial Counselors Inc. now owns 362,755 shares of the company’s stock valued at $23,249,000 after acquiring an additional 4,476 shares in the last quarter. Institutional investors own 74.60% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This report was first reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this report on another site, it was copied illegally and reposted in violation of United States & international trademark & copyright laws. The correct version of this report can be viewed at https://www.chaffeybreeze.com/2018/04/17/bank-of-america-boosts-merck-co-mrk-price-target-to-70-00.html.

Merck & Co. Company Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases.

Analyst Recommendations for Merck & Co. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply